Cannabis Science Inc (OTCMKTS:CBIS) shares were down 10.46% to $0.0338 on Monday and up 16.86% in after-hours trading. Share prices have been trading in a 52-week range of $0.01 to $0.08. The company has a market cap of $57.85 million at 2.31 billion shares outstanding.
In a press release over the weekend, Cannabis Science Inc revealed plans to initiate long-awaited clinical studies this month. The company has been planning to conduct a medication study, targeted at failing lung infections in pulmonary patients, and the first lab and extraction site is being completed at its new facility. It revealed that the study would not only be focused on the medications, but on the method of delivery as well.
In particular, Cannabis Science Inc is looking at IV delivery compared to traditional pills or inhaled medications. In their press release, they explained that introducing something to the human body through an IV, whether it be a certain medication, blood or, in this case, CBD/THC extract, the item goes directly to the right side of the heart, from there it is pushed within a beat or two straight to the lungs then your blood distributes the item throughout the body.
With that, CBD/THC therapy by IV, while not a cure for lung disease, is one of the only methods that seeks to go directly to the problem area without potency loss to treat the disease itself. Even if it gets trapped in the lungs, the data suggests it goes to work immediately making healthy lung tissue work more efficiently and some studies show improvement in damaged tissue as well.
“While we here at Cannabis Science are committed to the development of cannabinoid cased medications in this relatively new modern time of medical marijuana applications for health benefits, we also realize the importance of method of delivery and the ability to target these medications to the problem areas,” remarked CEO of Cannabis Science Inc Raymond Dabney.
“Cannabis Science is dedicated to being at the forefront of full service exploration of all uses of Cannabis Medications and the best delivery methods for those medications. There are years of exciting times ahead of Cannabis Science in this newly opening area of medications and the company is positioning itself and taking the necessary steps required to meet the ever growing demands and patient base that is building across our great nation,” he added.
He did acknowledge that growth has been painfully slow at times but continued to urge investors and interested patients to research and educate themselves to cannabis medications, adding that time after time cannabis has proven its medical use as a great tool in the battle against disease and pain.
Cannabis Science Inc is a company that is engaged in medical marijuana research and development. As such, it works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The company is also involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Aside from that, Cannabis Science Inc focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. Its subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.